In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smith & Nephew withdraw 185 BHR (Birmingham Hip Resurfacing) implants:

This article was originally published in Clinica

Executive Summary

Smith & Nephew has recalled 185 of its Birmingham Hip Resurfacing system after discovering that the implants had been incorrectly packaged by the subcontractor. The mistake led to different sized acetabular cups being mixed together. S&N said the error was limited to a small number of batches and that several implants have already been recovered in their packaging. The company added that it has warned, or is in the process of warning, all hospitals that have received the implants and are -working closely" with surgeons and patients on the appropriate corrective action. The UK and US regulatory authorities have also been notified about the recall.

You may also be interested in...



CMS Final Medicare Outpatient Rule Gives Patients More Surgical Site Choices, At Lower Costs

The US Medicare agency is offering more lower-cost alternative sites for 2021 surgical procedures to be covered under its OPPS and ASC final rule.

Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV

Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.

What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.

Topics

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel